Phase II trial of oral UFT and leucovorin in advanced gastric carcinoma

Yeul Hong Kim, Seong Kyoon Cheong, Jee Dong Lee, Jeong Sik Park, Sang Won Shin, Jun Suk Kim

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)


A phase II trial was performed with oral UFT plus leucovorin (LV) in 16 patients with advanced gastric carcinoma. Treatment consisted of UFT, 480 mg/m2/day, in conjunction with LV administered at 25 mg/m2/day per os in divided daily doses for 21 days followed by a 7-day rest period. The median age of the patients was 64 years, with a median World Health Organization (WHO) performance status of 2. One patient was previously treated with etoposide, doxorubicin, and cisplatin (EAP). A median of four courses of treatment were given per patient (range: 1-9). Among 14 evaluable patients, one patient achieved a complete response and 3 had partial responses (response rate: 28.5%, 95% confidence interval, 4.9 to 52.3%). Stable disease was reported in 5 patients (35.7%) and another 5 showed progression. The time to progression was 17, 18, 27, and 76+ weeks for the responding patients, respectively. The median duration of survival was 25 weeks (range: 10-76+) for 14 evaluable patients. All patients were evaluable for toxicity. The main toxicity was diarrhea and oral mucositis. Significant toxicity (WHO grade 3 or 4) included diarrhea in 7 patients (43.8%), oral mucositis in 2 (12.5%), and nausea/vomiting in 2, respectively. We conclude that oral UFT plus LV, an out-patient regimen, has a favorable activity in gastric carcinoma patients and has tolerable toxicities.

Original languageEnglish
Pages (from-to)212-216
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number2
Publication statusPublished - 1996 Apr


  • Advanced gastric carcinoma
  • Chemotherapy
  • Leucovorin
  • UFT

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Phase II trial of oral UFT and leucovorin in advanced gastric carcinoma'. Together they form a unique fingerprint.

Cite this